TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) released its quarterly earnings results on Monday. The company reported ($9.19) earnings per share (EPS) for the quarter, Zacks reports.
TransCode Therapeutics Price Performance
Shares of TransCode Therapeutics stock traded down $0.07 during trading hours on Wednesday, hitting $1.33. 16,601 shares of the company’s stock traded hands, compared to its average volume of 104,460. TransCode Therapeutics has a 12-month low of $1.28 and a 12-month high of $12.60. The stock has a market capitalization of $22.60 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. The company has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $5.65.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, TransCode Therapeutics presently has an average rating of “Sell”.
About TransCode Therapeutics
TransCode Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for cancer, with a focus on metastatic disease. Its research centers on using RNA therapeutics to target biological processes involved in cancer growth and spread. The company’s lead program, TTX-MC138, is designed to inhibit microRNA-10b, a molecule associated with cancer metastasis. TransCode is also advancing other investigational RNA-based programs aimed at cancer-related targets. These candidates remain in development and are not approved treatments.
Read More
- Five stocks we like better than TransCode Therapeutics
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
